MCID: CHR417
MIFTS: 56

Chronic Graft Versus Host Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Chronic Graft Versus Host Disease

MalaCards integrated aliases for Chronic Graft Versus Host Disease:

Name: Chronic Graft Versus Host Disease 53 59
Chronic Graft-Versus-Host Disease 55 72
Chronic Gvhd 53

Classifications:

Orphanet: 59  
Rare immunological diseases


External Ids:

MESH via Orphanet 45 D006086
ICD10 via Orphanet 34 T86.0
UMLS via Orphanet 73 C0867389
Orphanet 59 ORPHA99921
UMLS 72 C0867389

Summaries for Chronic Graft Versus Host Disease

NIH Rare Diseases : 53 Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown. It likely results from a complex immune-mediated interaction between the donor and recipient cells. Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.

MalaCards based summary : Chronic Graft Versus Host Disease, also known as chronic graft-versus-host disease, is related to graft-versus-host disease and hematopoietic stem cell transplantation. An important gene associated with Chronic Graft Versus Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Infliximab and Posaconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are poor wound healing and intermittent generalized erythematous papular rash

Related Diseases for Chronic Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Chronic Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 486)
# Related Disease Score Top Affiliating Genes
1 graft-versus-host disease 32.6 IL1A IL10 IFNG
2 hematopoietic stem cell transplantation 32.4 IL10 IFNG
3 acute graft versus host disease 32.0 IL2RA IL10 IFNG
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.4 TNFSF13B IL10 IFNG
5 myasthenia gravis 31.0 TNFSF13B IL10 IFNG
6 autoimmune disease 31.0 TNFSF13B IL2RA IL10 IFNG
7 scabies 30.7 IL1A IL10
8 chronic inflammatory demyelinating polyradiculoneuropathy 30.7 IFNG ALB
9 proliferative glomerulonephritis 30.6 IFNG CD79A
10 skin disease 30.6 IL1A IL10 IFNG CD79A
11 large granular lymphocyte leukemia 30.6 IL2RA IFNG
12 pure red-cell aplasia 30.6 IL2RA ALB
13 poliomyelitis 30.6 IL10 IFNG
14 keratoconjunctivitis sicca 30.4 IL1A IL10 CD79A ALB
15 lipoid nephrosis 30.4 IL10 CD79A ALB
16 myeloma, multiple 30.4 TNFSF13B CD79A ALB
17 polyradiculoneuropathy 30.4 IL10 IFNG ALB
18 hepatitis a 30.4 IL10 IFNG ALB
19 protein-losing enteropathy 30.3 CD79A ALB
20 meningitis 30.3 IL10 IFNG ALB
21 leprosy 3 30.3 IL10 IFNG
22 parotitis 30.2 CD79A ALB
23 hemophagocytic lymphohistiocytosis 30.2 IL2RA IL10 IFNG
24 alopecia areata 30.1 IL2RA IL1A IFNG
25 tick-borne encephalitis 30.0 IL10 ALB
26 lymphoma, non-hodgkin, familial 30.0 TNFSF13B IL2RA CD79A
27 ocular cicatricial pemphigoid 29.9 CD79A CD36
28 uveitis 29.9 IL2RA IL1A IL10 IFNG
29 tetanus 29.7 IL2RA IL10 IFNG CD79A
30 multiple sclerosis 29.7 TNFSF13B IL2RA IL10 IFNG
31 pulmonary fibrosis, idiopathic 29.6 IL1A IFNG CD36
32 connective tissue disease 29.5 TNFSF13B MICA IL1A IL10 IFNG
33 systemic lupus erythematosus 29.5 TNFSF13B IL2RA IL10 IFNG CD79A ALB
34 rheumatoid arthritis 29.2 TNFSF13B IL2RA IL1A IL10 IFNG
35 acquired immunodeficiency syndrome 28.4 IL2RA IL10 IFNG CD4 ALB
36 systemic scleroderma 10.8
37 bronchiolitis 10.7
38 bronchiolitis obliterans 10.7
39 lymphocytic leukemia 10.7
40 glomerulonephritis 10.6
41 aplastic anemia 10.6
42 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.6
43 scleroderma, familial progressive 10.6
44 cephalosporin allergy 10.6 IL10 IFNG
45 polymyositis 10.6
46 nickel allergic contact dermatitis 10.6 IL10 IFNG
47 baylisascariasis 10.6 IL10 IFNG
48 leukemia, acute lymphoblastic 10.6
49 pericardial tuberculosis 10.6 IL10 IFNG
50 fungal meningitis 10.6 IL10 IFNG

Graphical network of the top 20 diseases related to Chronic Graft Versus Host Disease:



Diseases related to Chronic Graft Versus Host Disease

Symptoms & Phenotypes for Chronic Graft Versus Host Disease

Human phenotypes related to Chronic Graft Versus Host Disease:

59 32 (show top 50) (show all 54)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 poor wound healing 59 32 hallmark (90%) Very frequent (99-80%) HP:0001058
2 intermittent generalized erythematous papular rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0007432
3 photophobia 59 32 frequent (33%) Frequent (79-30%) HP:0000613
4 nail dystrophy 59 32 frequent (33%) Frequent (79-30%) HP:0008404
5 erythema 59 32 frequent (33%) Frequent (79-30%) HP:0010783
6 xerostomia 59 32 frequent (33%) Frequent (79-30%) HP:0000217
7 abnormality of skin pigmentation 59 32 frequent (33%) Frequent (79-30%) HP:0001000
8 elevated hepatic transaminase 59 32 frequent (33%) Frequent (79-30%) HP:0002910
9 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
10 keratoconjunctivitis sicca 59 32 frequent (33%) Frequent (79-30%) HP:0001097
11 recurrent infections 59 32 frequent (33%) Frequent (79-30%) HP:0002719
12 bronchiectasis 59 32 frequent (33%) Frequent (79-30%) HP:0002110
13 onycholysis 59 32 frequent (33%) Frequent (79-30%) HP:0001806
14 recurrent corneal erosions 59 32 frequent (33%) Frequent (79-30%) HP:0000495
15 food intolerance 59 32 frequent (33%) Frequent (79-30%) HP:0012537
16 muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0001324
17 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
18 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
19 flexion contracture 59 32 occasional (7.5%) Occasional (29-5%) HP:0001371
20 gastroesophageal reflux 59 32 occasional (7.5%) Occasional (29-5%) HP:0002020
21 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
22 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
23 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
24 pancytopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001876
25 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
26 skin vesicle 59 32 occasional (7.5%) Occasional (29-5%) HP:0200037
27 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
28 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
29 hematuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000790
30 pulmonary infiltrates 59 32 occasional (7.5%) Occasional (29-5%) HP:0002113
31 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
32 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
33 chest pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0100749
34 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
35 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
36 pneumothorax 59 32 occasional (7.5%) Occasional (29-5%) HP:0002107
37 nausea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002018
38 pleural effusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0002202
39 obstructive lung disease 59 32 occasional (7.5%) Occasional (29-5%) HP:0006536
40 fasciitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100537
41 wheezing 59 32 occasional (7.5%) Occasional (29-5%) HP:0030828
42 esophageal ulceration 59 32 occasional (7.5%) Occasional (29-5%) HP:0004791
43 urinary bladder inflammation 59 32 occasional (7.5%) Occasional (29-5%) HP:0100577
44 esophageal stricture 59 32 occasional (7.5%) Occasional (29-5%) HP:0002043
45 phimosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001741
46 morphea 59 32 occasional (7.5%) Occasional (29-5%) HP:0012344
47 bronchiolitis obliterans 59 32 occasional (7.5%) Occasional (29-5%) HP:0011946
48 entrapment neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0012181
49 abnormal vagina morphology 32 occasional (7.5%) HP:0000142
50 thickened skin 59 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 8.8 CD4 MICA TNFSF13B

MGI Mouse Phenotypes related to Chronic Graft Versus Host Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.92 CD36 CD4 CD79A IFNG IL10 IL1A
2 digestive/alimentary MP:0005381 9.88 ALB CD36 CD4 IFNG IL10 IL2RA
3 homeostasis/metabolism MP:0005376 9.86 ALB CD36 CD4 CD79A IFNG IL10
4 endocrine/exocrine gland MP:0005379 9.85 ALB CD36 CD4 IFNG IL10 IL2RA
5 immune system MP:0005387 9.76 CD36 CD4 CD79A IFNG IL10 IL1A
6 liver/biliary system MP:0005370 9.35 ALB CD36 CD79A IFNG IL10
7 neoplasm MP:0002006 9.02 ALB CD79A IFNG IL10 IL1A

Drugs & Therapeutics for Chronic Graft Versus Host Disease

Drugs for Chronic Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 256)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4 170277-31-3
2
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
5
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
6 Antiparasitic Agents Phase 4
7 Antiprotozoal Agents Phase 4
8 glucocorticoids Phase 4
9 Hormone Antagonists Phase 4
10 Hormones Phase 4
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
12 Pharmaceutical Solutions Phase 4
13 14-alpha Demethylase Inhibitors Phase 4
14 Steroid Synthesis Inhibitors Phase 4
15 Cytochrome P-450 Enzyme Inhibitors Phase 4
16 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
17 Cytochrome P-450 CYP3A Inhibitors Phase 4
18
Hydroxyitraconazole Phase 4
19
Idarubicin Approved Phase 3 58957-92-9 42890
20
Hydroxychloroquine Approved Phase 3 118-42-3 3652
21
Clobetasol Approved, Experimental, Investigational Phase 3 25122-46-7, 25122-41-2 32798 5311051
22
Budesonide Approved Phase 3 51333-22-3 63006 5281004
23
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
24
Acyclovir Approved Phase 3 59277-89-3 2022
25
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
26
Atorvastatin Approved Phase 3 134523-00-5 60823
27
Sodium citrate Approved, Investigational Phase 3 68-04-2
28
Azithromycin Approved Phase 3 83905-01-5 447043 55185
29
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
30
Daunorubicin Approved Phase 3 20830-81-3 30323
31
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 23925 27284
32
Hydroxyurea Approved Phase 3 127-07-1 3657
33
Peginterferon alfa-2b Approved Phase 2, Phase 3 99210-65-8, 215647-85-1
34
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
36
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
37 Antimalarials Phase 3
38 Respiratory System Agents Phase 3
39 Anti-Asthmatic Agents Phase 3
40 Ionophores Phase 3
41 Bronchodilator Agents Phase 3
42 Muromonab-CD3 Phase 3
43 Imatinib Mesylate Phase 3 220127-57-1 123596
44 Janus Kinase Inhibitors Phase 3
45 Lipid Regulating Agents Phase 3
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
47 Hypolipidemic Agents Phase 3
48 Anticholesteremic Agents Phase 3
49 Citrate Phase 3
50 Anticoagulants Phase 3

Interventional clinical trials:

(show top 50) (show all 609)
# Name Status NCT ID Phase Drugs
1 Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
2 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
3 Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies Recruiting NCT01856803 Phase 4 anti thymoglobulin
4 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
5 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
6 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Not yet recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
7 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
8 Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
9 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
10 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
11 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
12 Prospective Controlled Clinical Study of Allogeneic Stem Cell Transplantation With Reduced Conditioning (RICT) Versus Best Standard of Care in Acute Myeloid Leukemia (AML)in First Complete Remission (CR) Unknown status NCT00342316 Phase 3
13 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
14 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
15 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
16 Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3 cyclosporine;hydroxychloroquine;prednisone;tacrolimus
17 A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN Protocol #0801) Completed NCT01106833 Phase 2, Phase 3 Sirolimus + calcineurin inhibitor + prednisone;Sirolimus + prednisone
18 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
19 Randomized Double-blid Clinical Trial Comparing the Topical Treatment With Clobetasol and Dexamethasone for Oral Lesions of Chronic Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone
20 A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT01020175 Phase 3
21 A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201) Completed NCT00075816 Phase 3
22 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
23 A Prospective Randomized Study Comparing Rapamune and Tacrolimus vs. Cyclosporine and Methotrexate as Immune Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation, Using HLA-A, -B, -DRβ1 Identical Related or Unrelated Donors. A Nordic Multicenter Study. Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate
24 An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
25 Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
26 A PHASE III RANDOMIZED STUDY COMPARING G-CSF MOBILIZED PERIPHERAL BLOOD STEM CELLS WITH MARROW AS THE SOURCE OF STEM CELLS FOR ALLOGENEIC TRANSPLANTS FROM HLA IDENTICAL, RELATED DONORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA Completed NCT00002789 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
27 Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission. Completed NCT01191957 Phase 3 Busulphan plus Cyclophosphamide;Busulphan plus Fludarabine
28 Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors Completed NCT01295710 Phase 3
29 Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD Completed NCT00887263 Phase 3 Budesonide;Placebo
30 Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease Completed NCT00034645 Phase 3 Posaconazole oral suspension
31 Nonmyeloablative Allogeneic Stem Cell Transplantation in Elderly Patients With Hematological Malignancies:Results From the GITMO (Gruppo Italiano Trapianto Midollo Osseo)Multicenter Prospective Clinical Trial Completed NCT00382759 Phase 2, Phase 3
32 A Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Thymoglobuline in Non-myeloablative Allogeneic Hemapoietic Stem-cell Transplantation (NST) Completed NCT00130754 Phase 3 Thymoglobuline
33 Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens Completed NCT00822393 Phase 3 Busulfan;Treosulfan
34 Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo Completed NCT00053976 Phase 3 methylprednisolone;Placebo
35 A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia Completed NCT00382109 Phase 3 thiotepa;cyclophosphamide;tacrolimus;methotrexate;sirolimus
36 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
37 Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
38 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
39 Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China. Recruiting NCT02291770 Phase 3
40 GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Recruiting NCT03584516 Phase 3 Itacitinib;Placebo;Methylprednisolone;Prednisone
41 Randomized Study of Atorvastatin Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Chronic Graft Versus Host Disease Allogeneic Stem Cell Transplantation From Matched Unrelated Donors Recruiting NCT03066466 Phase 3 Atorvastatin;Methotrexate;Tacrolimus
42 A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3) Recruiting NCT03112603 Phase 3 Ruxolitinib;Extracorporeal photopheresis (ECP);Low-dose methotrexate (MTX);Mycophenolate mofetil (MMF);mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus);Infliximab;Rituximab;Pentostatin;Imatinib;Ibrutinib
43 Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial Recruiting NCT03818334 Phase 2, Phase 3 Cyclophosphamide;ATG
44 BT13BTθ51 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha Beta T Cell and B Cell Depletion For Patients With Hematologic Malignancies Recruiting NCT02600208 Phase 2, Phase 3
45 Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (INTEGRATE) Active, not recruiting NCT02959944 Phase 3 ibrutinib;Placebo;Prednisone
46 A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) Active, not recruiting NCT03474679 Phase 3 Ibrutinib
47 A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II) Active, not recruiting NCT02345850 Phase 3 Cyclophosphamide;Tacrolimus;Methotrexate
48 The Comparison of Transplantation From Family-mismatched/Haploidentical Donors With Matched Unrelated Donors in Adult Patients With Acute Myeloid Leukemia Active, not recruiting NCT01751997 Phase 2, Phase 3 Transplants from 8/8-matched Unrelated donors;Transplants from family-mismatched/haploidentical donors
49 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age &gt;/= 60 Years) Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
50 Evaluation of the Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting NCT01959100 Phase 3 Azithromycin;Placebo

Search NIH Clinical Center for Chronic Graft Versus Host Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Thalidomide

Genetic Tests for Chronic Graft Versus Host Disease

Anatomical Context for Chronic Graft Versus Host Disease

MalaCards organs/tissues related to Chronic Graft Versus Host Disease:

41
Bone, Bone Marrow, T Cells, Myeloid, Skin, B Cells, Eye

Publications for Chronic Graft Versus Host Disease

Articles related to Chronic Graft Versus Host Disease:

(show top 50) (show all 3720)
# Title Authors PMID Year
1
Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse. 9 38
19285638 2009
2
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. 9 38
16239431 2006
3
Granulocyte colony-stimulating factor--primed allogeneic bone marrow transplants: capturing the advantages of blood stem cell transplants without increased risk of chronic graft-versus-host disease. 9 38
10975509 2000
4
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. 38
31312927 2019
5
Role of B cells in chronic graft-versus-host disease after allogeneic stem cell transplantation in children and adolescents. 38
31134622 2019
6
Dyskeratosis Congenita and Corneal Refractive Surgery. 38
31313220 2019
7
Oral Complications of Chronic Graft-Versus-Host Disease. 38
31425593 2019
8
Impact of dermatology consultation on the care of children with chronic graft-versus-host disease of the skin. 38
30677461 2019
9
Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease-single center experience. 38
31375860 2019
10
Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. 38
31431716 2019
11
Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients. 38
30993415 2019
12
HSV-associated erythema multiforme in a patient after hematopoietic stem cell transplantation. 38
31414706 2019
13
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen. 38
30951841 2019
14
Pediatric unmanipulated haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide and reduced intensity, TBI-free conditioning regimens in salvage transplantations. 38
31430069 2019
15
Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. 38
30518981 2019
16
The Chronic Graft-vs.-Host Disease Failure-Free Survival (cGVHD-FFS) index. 38
31394265 2019
17
Allogeneic bone marrow versus peripheral blood stem cell transplantation for hematological malignancies in children: a systematic review and meta-analysis. 38
31394270 2019
18
Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation. 38
30959161 2019
19
Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. 38
31048087 2019
20
A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA haploidentical donors. 38
31432532 2019
21
Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter? 38
30626239 2019
22
Neurological adverse events post allogeneic hematopoietic cell transplantation: major determinants of morbidity and mortality. 38
31087160 2019
23
Updated clinical outcomes of hematopoietic stem cell transplantation using myeloablative total body irradiation with ovarian shielding to preserve fertility. 38
31394267 2019
24
Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation. 38
31345792 2019
25
Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. 38
31412155 2019
26
Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin. 38
31413093 2019
27
Coronary artery involvement in chronic graft-versus-host disease presenting as sudden cardiac arrest. 38
31124210 2019
28
Chronic Graft versus host disease. Atypical vesicular presentation. 38
31302980 2019
29
Pediatric chronic graft-versus-host disease. 38
31320368 2019
30
Clinical and Dermoscopic Evaluation of Melanocytic Lesions in Patients with Chronic Graft Versus Host Disease. 38
30938827 2019
31
Negative impact of chronic graft-versus-host disease and glucocorticoid on the recovery of physical function after allogeneic hematopoietic stem cell transplantation. 38
30337699 2019
32
Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. 38
30876928 2019
33
Ablative Fractional Laser Resurfacing for Treatment of Sclerosis and Contractures in Chronic Graft-Versus-Host Disease: A Pilot Study. 38
31374309 2019
34
A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. 38
30655371 2019
35
Effect of antithymocyte globulin on HLA-mismatched unrelated transplantation. 38
30680666 2019
36
HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. 38
31104211 2019
37
Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin. 38
31324882 2019
38
Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation. 38
31080050 2019
39
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. 38
30871976 2019
40
Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. 38
30919947 2019
41
Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis. 38
31265729 2019
42
New graft manipulation strategies improve the outcome of mismatched stem cell transplantation in children with primary immunodeficiencies. 38
30731121 2019
43
Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. 38
31043425 2019
44
Impact of a Nutritional Risk Index on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation. 38
31284071 2019
45
Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. 38
31332045 2019
46
Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects. 38
31282592 2019
47
Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. 38
31262738 2019
48
Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. 38
31309713 2019
49
Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with Sjögren's syndrome: Case series. 38
31335688 2019
50
CD8+CD103+ iTregs Inhibit Chronic Graft-versus-Host Disease with Lupus Nephritis by the Increased Expression of CD39. 38
31402273 2019

Variations for Chronic Graft Versus Host Disease

Expression for Chronic Graft Versus Host Disease

Search GEO for disease gene expression data for Chronic Graft Versus Host Disease.

Pathways for Chronic Graft Versus Host Disease

Pathways related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 TNFSF13B MICA IL2RA IL1A IL10 IFNG
2
Show member pathways
13.48 TNFSF13B IL2RA IL1A IL10 IFNG CD4
3
Show member pathways
13.34 TNFSF13B IL2RA IL1A IL10 IFNG CD4
4
Show member pathways
13.22 TNFSF13B IL2RA IL1A IL10 CD4
5
Show member pathways
13.11 TNFSF13B IL2RA IL1A IL10 IFNG CD4
6
Show member pathways
13.1 TNFSF13B IL2RA IL1A IL10 CD4
7
Show member pathways
12.47 IL2RA IL10 IFNG CD79A CD4
8
Show member pathways
12.44 TNFSF13B MICA IL2RA IL1A IL10 IFNG
9
Show member pathways
12.41 IL2RA IL1A IL10 IFNG CD4
10
Show member pathways
12.39 IL1A IL10 IFNG CD4
11 12.35 TNFSF13B IL2RA IL10 IFNG CD79A
12
Show member pathways
12.1 IL1A IL10 IFNG
13
Show member pathways
12.09 IL2RA IL1A IL10 IFNG
14 12.07 IL1A IL10 IFNG
15
Show member pathways
11.91 IL10 IFNG CD4
16 11.86 TNFSF13B IL1A IFNG
17 11.83 IL1A IL10 CD36
18
Show member pathways
11.82 IL2RA IFNG CD4
19
Show member pathways
11.75 TNFSF13B IL2RA IL1A IL10 IFNG CD4
20 11.73 IL2RA IL10 IFNG
21 11.72 TNFSF13B IL1A IFNG
22 11.69 IL2RA IL1A CD4 CD36
23 11.61 IL10 IFNG CD4
24 11.59 IL10 IFNG CD36
25 11.57 IL2RA IL10 IFNG CD4
26 11.4 IL10 IFNG CD36
27 11.29 IL2RA IL10 IFNG CD4
28 11.24 CD79A CD4
29 11.23 IL10 IFNG
30 11.21 IL1A IL10
31 11.18 IL2RA IFNG
32 11.16 IL2RA IL10 IFNG CD79A CD4 CD36
33
Show member pathways
11.12 IL2RA IFNG
34 11.12 IL2RA IFNG CD4
35 11.07 IL10 IFNG
36 11.05 TNFSF13B IL1A IL10
37 10.93 IL1A IFNG
38 10.72 IL1A IL10 IFNG CD4

GO Terms for Chronic Graft Versus Host Disease

Cellular components related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.46 MICA IL2RA CD4 CD36
2 membrane raft GO:0045121 9.43 CD79A CD4 CD36
3 external side of plasma membrane GO:0009897 9.26 IL2RA CD79A CD4 CD36
4 extracellular space GO:0005615 9.17 TNFSF13B MICA IL1A IL10 IFNG CD36

Biological processes related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.78 TNFSF13B IL2RA CD79A CD4
2 cytokine-mediated signaling pathway GO:0019221 9.55 IL2RA IL1A IL10 CD4 CD36
3 negative regulation of T cell proliferation GO:0042130 9.51 IL2RA IL10
4 B cell proliferation GO:0042100 9.49 IL10 CD79A
5 positive regulation of cytokine secretion GO:0050715 9.46 IL1A IL10
6 positive regulation of interleukin-12 production GO:0032735 9.43 IFNG CD36
7 positive regulation of T cell proliferation GO:0042102 9.43 TNFSF13B IL2RA CD4
8 regulation of regulatory T cell differentiation GO:0045589 9.4 IL2RA IFNG
9 negative regulation of growth of symbiont in host GO:0044130 9.37 IL10 CD36
10 cell surface receptor signaling pathway GO:0007166 9.35 IL2RA IFNG CD79A CD4 CD36
11 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.32 IL1A CD4
12 immune response GO:0006955 9.23 TNFSF13B MICA IL2RA IL1A IL10 IFNG

Molecular functions related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.65 TNFSF13B MICA IL2RA IL1A IL10 IFNG
2 cytokine activity GO:0005125 8.92 TNFSF13B IL1A IL10 IFNG

Sources for Chronic Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....